EX-10.27 4 fold-12312021xex1027.htm EX-10.27
PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
CONFIDENTIAL
Execution Version
FOURTH AMENDMENT TO AMENDED AND RESTATED
RESEARCH, COLLABORATION AND LICENSE AGREEMENT
This FOURTH AMENDMENT (the “Amendment”), dated December 23, 2020 (the “Amendment Date”), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
WHEREAS, the Parties entered into a Research, Collaboration & License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration & License Agreement dated May 28, 2019 (the “Collaboration Agreement”), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, and the Third Amendment dated December 23, 2020, pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications; and
WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
1.Licensee has exercised its Exploratory Indication Option to start a Research Program for [***] and the parties have agreed on a Research Plan and a Research Plan Budget. The Research Plan and timeline for the [***] program is contained in the updated Exhibit B to this Fourth Amendment. The Research Program Budget for the [***] program is contained in the updated Exhibit C to this Fourth Amendment. The payment schedule set forth in Exhibit C is incremental to the payment schedule contained in the Third Amendment of the Collaboration Agreement.
2.Within [***] business days following the Amendment Date, Licensee will pay to Penn a non-refundable, non-creditable payment in the amount of [***] by wire transfer of immediately available funds (“New Indication Option Fee”) pursuant to Section 6.6 of the Collaboration Agreement.
3.This Fourth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Fourth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this

Fourth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.
4.All terms and conditions of the Collaboration Agreement not changed by this Fourth Amendment shall remain in full force and effect.
5.Signatures on this Fourth Amendment may be communicated by facsimile or e- mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.
[Remainder of the page intentionally left blank; signature page follows.]

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
AMICUS THERAPEUTICS, INC.
By: /s/ John S. Swartley By: /s/ Jeff Castelli
Name: John S. Swartley, PhD Name: Jeff Castelli, PhD
Title: Associate Vice Provost for Research and Managing Director, Penn Center for Innovation
Title: Chief Development Officer
Read and Acknowledged:
By: /s/ James Wilson
Name: Dr. James M. Wilson
Title: Director, Gene Therapy Program

Exhibit B Research Plan
[***]

Exhibit C
Research Program Budget and Payment Schedule
[***]